glp 1 novo Nordisk, Eli Lilly cut GLP-1 drug costs under Medicare Details of failed studies cast

doi: 10.1016/j.cmet.2011.09.010

The FDA has approved certain medications (Victoza, Ozempic, Trulicity) for cardiovascular risk reduction in patients with established cardiovascular disease and type 2 diabetes, and Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease who have overweight or obesity

There was no significant difference in weight loss in patients with type 2 diabetes on maximally tolerated oral hypoglycemic therapy who were either initiated on liraglutide 1.8 mg per day or exenatide 10 g twice daily [61]

I get this question every week, and it matters because these are not all the same drug

10.1016/j.jhep.2023.07.033

Diabetes 63 (2), 410420